Transverse Medical Inc

Transverse Medical Inc (TMI) is a biotechnology, health care, and manufacturing company based in the United States, founded in 2011. The company is focused on developing the POINT-GUARD™ Cerebral Embolic Protection (CEP) medical device to address the unmet need for Full Brain Protection and the clinical problem of periprocedural Stroke in Structural Heart Procedures, such as Transcatheter Aortic Valve Replacement (TAVR). The device aims to safeguard the brain and treat the heart. However, it's important to note that POINT-GUARD™ is not cleared for sale by any regulatory authority at this time. The most recent funding round for Transverse Medical Inc was a $6.63M Venture Round investment, which took place on 18 August 2023. At present, no specific information is available regarding the participating investors in this round. The company's mission and focus on addressing critical unmet needs in the healthcare industry showcase its potential for making a significant impact. Transverse Medical Inc's innovative approach to enhancing patient outcomes in critical medical procedures positions it as a compelling investment opportunity in the biotechnology and healthcare sectors.